Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: A randomized, double-blind, placebo-controlled study

Department of Medicine, Institute for Diabetes and Metabolism, Medical University, Graz, Austria.
International Journal of Obesity (Impact Factor: 5). 02/2007; 31(1):138-46. DOI: 10.1038/sj.ijo.0803382
Source: PubMed


To investigate the efficacy and safety of topiramate in obese subjects with type 2 diabetes treated with metformin.
This was a multicenter, double-blind, placebo-controlled trial. All subjects received a non-pharmacological program of diet, exercise and behavioral modification throughout the study; the assigned diet was 600 kcal/day less than the subject's individually calculated energy expenditure. After a 6-week single-blind placebo run-in, subjects were randomized to placebo, topiramate 96 mg/day or topiramate 192 mg/day. Following an 8-week titration period, subjects remained on their assigned dose for 52 weeks. However, the sponsor ended the study early in order to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. A total of 646 obese men and women (age: 18-75 years, body mass index: 27-50 kg/m(2)) with an established history of type 2 diabetes mellitus controlled by metformin monotherapy were randomized. Efficacy was assessed in a pre-determined modified intent-to-treat (MITT) population of 307 subjects whose randomization date would have allowed them to complete 24 weeks on study medication before the announcement of study termination.
Joint primary efficacy parameters were mean percent change in weight and change in glycosylated hemoglobin (HbA(1c)) from baseline to week 24.
Subjects in the placebo, topiramate 96 mg/day and topiramate 192 mg/day groups lost 1.7%, 4.5% (P<0.001) and 6.5% (P<0.001), respectively, of their baseline body weight and had absolute decreases in HbA(1c) of 0.1%, 0.4% (P<0.001) and 0.6% (P<0.001) (MITT, last observation carried forward). Topiramate-treated subjects also experienced statistically significant decreases in systolic blood pressure. Most common adverse events were paresthesia and events related to the central nervous system.
Topiramate was effective for weight reduction and improvement in glycemic control in obese subjects with type 2 diabetes treated with metformin monotherapy. Further study in obese diabetics is warranted.

Download full-text


Available from: Ewan Masson, Mar 13, 2015
    • "Topiramate has also received approval for the prophylaxis of migraine. Other indications for which topiramate may be effective include neuropathic pain syndromes,[1] alcoholism but not necessarily smoking,[2–7] obesity,[8] eating disorders,[9] and drug-induced weight gain.[1011] Although efficacy in posttraumatic stress disorder is uncertain,[12] the drug is ineffective in bipolar disorder.[1314] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Some patients experience cognitive disturbances with topiramate. A 19-year-old bipolar woman and her 46-year-old mother with paranoid personality disorder both used topiramate (25-50 mg/day) off-label for weight loss. Both women suffer from learning disorders, and both are excessively sensitive to the sedative adverse effects of psychotropic medications. Within days of starting topiramate, the women began to exhibit troublesome word- and phrase-repetition and word substitution, both occurring only in their written expression. The symptoms were associated with mild sedation, persisted during two weeks of topiramate treatment, and remitted days after topiramate was withdrawn. The presence of the learning disorders and the sensitivity to the sedative adverse effects of drugs may explain why cognitive adverse effects, known to occur with topiramate, developed at the low dose of 25-50 mg/day. The proclivity of topiramate to affect language functions and a possible familial vulnerability herein may explain why the women explained similar, language-specific symptoms. An investigation of topiramate-induced cognitive impairments in family members with epilepsy may throw light on the subject.
    Indian Journal of Psychiatry 07/2010; 52(3):260-3. DOI:10.4103/0019-5545.70986
  • Source
    • "Several clinical studies showed that treatment with TPM is associated with significant weight loss of the patients, in contrast with the effects of traditional mood stabilizers generally leading to body weight gain [3] [4] [5] [6]. In a recent study following 307 obese subjects with type 2 diabetes over 1 year, TPM was effective for weight reduction and improvement in glycemic control [7]. The mechanisms at the basis of these effects have not been elucidated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Topiramate (Topamax), primarily prescribed against epilepsy, was reported to reduce body weight and to ameliorate glycemic control in obese patients with diabetes. In rodent models of obesity and diabetes, topiramate treatment counteracts hyperglycemia and increases insulin levels upon glucose tolerance test. These observations suggest that topiramate might exert direct action on insulin secreting cells, in particular regarding obesity associated beta-cell dysfunction. In this study, INS-1E beta-cells were exposed for 3 days to the fatty acid oleate (0.4mM) and concomitantly treated with therapeutic concentrations of topiramate before measurements of insulin secretion and metabolic parameters. In healthy cells, topiramate had no acute or chronic effects on insulin release. Exposure of INS-1E cells to oleate for 3 days increased insulin release at basal 2.5mM glucose and blunted the response to stimulatory glucose concentration (15mM). Such lipotoxic effects were associated with impaired mitochondrial function, as evidenced by partial loss of resting mitochondrial membrane potential and reduced hyperpolarization in response to glucose. Oil-red-O staining and triglyceride measurements revealed lipid accumulation in oleate treated cells. Topiramate treatment counteracted oleate-induced lipid load and partially protected against mitochondrial membrane dysfunction. In particular, topiramate restored glucose stimulated insulin secretion, essentially by maintaining low insulin release at basal glucose. Topiramate increased expression of the nutrient sensor PPARalpha and of the mitochondrial fatty acid carrier CPT-1, correlating with enhancement of beta-oxidation rate. The data demonstrate that a drug originally used as mood stabilizer exerts a direct action on beta-cells, protecting against lipid-induced dysfunction.
    Biochemical Pharmacology 11/2006; 72(8):965-73. DOI:10.1016/j.bcp.2006.07.013 · 5.01 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: METFORMIN USE IS PROBABLY NOT LINKED WITH RISK OF LACTIC ACIDOSIS Metformin, a medication used to lower glucose levels in patients with diabetes mellitus, has long been thought to increase the risk for a metabolic disorder known as lactic acidosis. This review summarised data from all known comparative and observational studies lasting longer than one month, and found no cases of fatal or nonfatal lactic acidosis in 35,619 patient-years of metformin use, or in 30,002 patient-years for those not on metformin. Average lactate levels measured during metformin treatment were no different than for placebo or for other medications used to treat diabetes. In summary, there is no evidence at present that metformin is associated with an increased risk for lactic acidosis if prescribed under the study conditions, taking into account contra-indications.
    Cochrane database of systematic reviews (Online) 02/2006; 4(1):CD002967. DOI:10.1002/14651858.CD002967.pub2 · 6.03 Impact Factor
Show more